본문 바로가기
KERD
논문KCI 등재

Efficacy and Safety of Anti-CGRP Monoclonal Antibodies in Prevention of Chronic Migraine: A Bayesian Network Meta-analysis

Rituparna Maiti|Anand Srinivasan|Mundot Puliappadamb Haridas|Amruta Tripathy
대한정신약물학회 (Korean College of Neuropsychopharmacology)|2024.02|Clinical Psychopharmacology and Neuroscience|제22권 제1호|pp. 23-32|DOI 10.9758/cpn.23.1109

2

조회

0

다운로드

0

인용

0

참고문헌

키워드

AntibodiesMigrainemonoclonalCalcitonin-gene-related peptideNetwork meta-analysis.

초록

Due to the unmet needs in the management of migraine, a primary headache, and disabling disorder, the past decade has focused on developing monoclonal antibodies (mAbs) against the calcitonin-gene-related peptide (CGRP) as migraine prophylactic agents. The objective of the study was to evaluate the efficacy and safety of various anti-CGRP mAbs in the prevention of chronic migraine. Network meta-analysis (NMA) was performed using the Bayesian framework to estimate the efficacy and safety of mAbs after performing a literature search in PubMed, MEDLINE, Cochrane database, and International Clinical Trial Registry Platform (ICTRP). The outcomes calculated were in terms of mean difference (MD) or odds ratio (OR) with a 95% credible interval (95%CrI). Network graphs were constructed and node-split analysis was done to analyze the inconsistency. The NMA included a total of 10 clinical trials. Galacanezumab (120 mg) (MD: −2.7; 95%CrI: −4.8 to −0.83) was found to be better than other mAbs in terms of the difference in mean migraine days (MMD). Fremanezumab quarterly dose administration showed the best response (OR: 2.9; 95%CrI: 1.9 to 4.6) in terms of responder rate. Eptinezumab was found to be safer (OR: 0.88; 95%CrI: 0.61− 1.3) as compared to other mAbs in terms of the rate of adverse events. Fremanezumab (quarterly) ranked better in terms of response rate, and eptinezumab was found to be the safest in the prophylactic management of migraine. Galacenequmab was better at reducing MMD. Further studies are needed to evaluate the long-term safety, efficacy, and use of mAbs in migraine patients.

Abstract

Due to the unmet needs in the management of migraine, a primary headache, and disabling disorder, the past decade has focused on developing monoclonal antibodies (mAbs) against the calcitonin-gene-related peptide (CGRP) as migraine prophylactic agents. The objective of the study was to evaluate the efficacy and safety of various anti-CGRP mAbs in the prevention of chronic migraine. Network meta-analysis (NMA) was performed using the Bayesian framework to estimate the efficacy and safety of mAbs after performing a literature search in PubMed, MEDLINE, Cochrane database, and International Clinical Trial Registry Platform (ICTRP). The outcomes calculated were in terms of mean difference (MD) or odds ratio (OR) with a 95% credible interval (95%CrI). Network graphs were constructed and node-split analysis was done to analyze the inconsistency. The NMA included a total of 10 clinical trials. Galacanezumab (120 mg) (MD: −2.7; 95%CrI: −4.8 to −0.83) was found to be better than other mAbs in terms of the difference in mean migraine days (MMD). Fremanezumab quarterly dose administration showed the best response (OR: 2.9; 95%CrI: 1.9 to 4.6) in terms of responder rate. Eptinezumab was found to be safer (OR: 0.88; 95%CrI: 0.61− 1.3) as compared to other mAbs in terms of the rate of adverse events. Fremanezumab (quarterly) ranked better in terms of response rate, and eptinezumab was found to be the safest in the prophylactic management of migraine. Galacenequmab was better at reducing MMD. Further studies are needed to evaluate the long-term safety, efficacy, and use of mAbs in migraine patients.

참고문헌 (39)

  1. GBD 2016 Disease, "Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016 : A systematic analysis for the Global Burden of Disease Study 2016", Lancet, 390, pp.1211~1259 (2017)
  2. Headache Classification Committee of the International Headache Society(IHS), "The international classification of headache disorders, 3rd edition(beta version)", Cephalalgia, 33, pp.629~808 (2013)
  3. Bigal ME, "Chronic migraine in the population : Burden, diagnosis, and satisfaction with treatment", Neurology, 71, pp.559~566 (2008)
  4. Edvinsson L, "CGRP as the target of new migraine therapies-successful translation from bench to clinic", Nat Rev Neurol, 14, pp.338~350 (2018)
  5. Scuteri D, "New trends in migraine pharmacology : Targeting calcitonin gene-related peptide(CGRP)with monoclonal antibodies", Front Pharmacol, 10, pp.363~ (2019)
  6. Russo AF, "Calcitonin gene-related peptide(CGRP) : A new target for migraine", Annu Rev Pharmacol Toxicol, 55, pp.533~552 (2015)
  7. Goadsby PJ, "Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system", Ann Neurol, 23, pp.193~196 (1988)
  8. Olesen J, "Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine", N Engl J Med, 350, pp.1104~1110 (2004)
  9. Wu H, "Humanized antibodies and their applications", Methods, 36, pp.1~2 (2005)
  10. Dodick DW, "ARISE : A Phase 3 randomized trial of erenumab for episodic migraine", Cephalalgia, 38, pp.1026~1037 (2018)
  11. Dodick DW, "Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine : A randomised, double-blind, placebocontrolled, exploratory phase 2 trial", Lancet Neurol, 13, pp.1100~1107 (2014)
  12. Detke HC, "Galcanezumab in chronic migraine : The randomized, double-blind, placebo-controlled REGAIN study", Neurology, 91, pp.e2211~e2221 (2018)
  13. Martelletti P, "The application of CGRP(r)monoclonal antibodies in migraine spectrum : Needs and priorities", BioDrugs, 31, pp.483~485 (2017)
  14. Reuter U, "A review of monoclonal antibody therapies and other preventative treatments in migraine", Headache, 58(Suppl 1), pp.48~59 (2018)
  15. Stauffer VL, "Evaluation of galcanezumab for the prevention of episodic migraine : The EVOLVE-1 randomized clinical trial", JAMA Neurol, 75, pp.1080~1088 (2018)
  16. Ferrari MD, "Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes(FOCUS) : A randomised, double-blind, placebo-controlled, phase 3b trial", Lancet, 394, pp.1030~1040 (2019)
  17. Ashina M, "Eptinezumab in episodic migraine : A randomized, double-blind, placebo-controlled study(PROMISE-1)", Cephalalgia, 40, pp.241~254 (2020)
  18. Goadsby PJ, "A controlled trial of erenumab for episodic migraine", N Engl J Med, 377, pp.2123~2132 (2017)
  19. Drevon D, "Intercoder reliability and validity of WebPlotDigitizer in extracting graphed data", Behav Modif, 41, pp.323~339 (2017)
  20. Wan X, "Estimating the sample mean and standard deviation from the sample size, median, range and", or interquartile range, 2014, pp.14, 135~
  21. van Valkenhoef G, "Automated generation of node-splitting models for assessment of inconsistency in network meta-analysis", Res Synth Methods, 7, pp.80~93 (2016)
  22. Cohen JM, "Fremanezumab as add-on treatment for patients treated with other migraine preventive medicines", Headache, 57, pp.1375~1384 (2017)
  23. Bigal ME, "TEV-48125 for the preventive treatment of chronic migraine : Efficacy at early time points", Neurology, 87, pp.41~48 (2016)
  24. Mulleners WM, "Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed(CONQUER) : A multicentre, randomised, double-blind, placebo-controlled, phase 3b trial", Lancet Neurol, 19, pp.814~825 (2020)
  25. Winner PK, "Early onset of efficacy with fremanezumab for the preventive treatment of chronic migraine", Headache, 59, pp.1743~1752 (2019)
  26. Goadsby PJ, "Long-term safety, tolerability, and efficacy of fremanezumab in migraine : A randomized study", Neurology, 95, pp.e2487~e2499 (2020)
  27. Lipton RB, "Efficacy and safety of eptinezumab in patients with chronic migraine : PROMISE-2", Neurology, 94, pp.e1365~e1377 (2020)
  28. Silberstein SD, "Fremanezumab for the preventive treatment of chronic migraine", N Engl J Med, 377, pp.2113~2122 (2017)
  29. Tepper S, "Safety and efficacy of erenumab for preventive treatment of chronic migraine : A randomised, double-blind, placebo-controlled phase 2 trial", Lancet Neurol, 16, pp.425~434 (2017)
  30. Dalton JE, "Publication bias : The elephant in the review", Anesth Analg, 123, pp.812~813 (2016)
  31. Hou M, "The effect and safety of monoclonal antibodies to calcitonin gene-related peptide and its receptor on migraine : A systematic review and meta-analysis", J Headache Pain, 18, pp.42~ (2017)
  32. Chen YY, "Calcitonin gene-related peptide monoclonal antibodies versus botulinum neurotoxin a in the preventive treatment of chronic migraine : An adjusted indirect treatment comparison meta-analysis", Front Pharmacol, 12, pp.671845~ (2021)
  33. Soni P, "Efficacy and safety of anti-calcitonin generelated peptide monoclonal antibodies for treatment of chronic migraine : A systematic review and network meta-analysis", Clin Neurol Neurosurg, 209, pp.106893~ (2021)
  34. Yang CP, "Comparative effectiveness and tolerability of the pharmacology of monoclonal antibodies targeting the calcitonin gene-related peptide and its receptor for the prevention of chronic migraine : A network meta-analysis of randomized controlled trials", Neurotherapeutics, 18, pp.2639~2650 (2021)
  35. Messina R, "Safety and tolerability of monoclonal antibodies targeting the CGRP pathway and gepants in migraine prevention : A systematic review and network meta-analysis", Cephalalgia, 43, pp.3331024231152169~ (2023)
  36. Russell FA, "Calcitonin gene-related peptide : Physiology and pathophysiology", Physiol Rev, 94, pp.1099~1142 (2014)
  37. Loder E, "The 2012 AHS", AAN guidelines for prevention of episodic migraine : A summary and comparison with other recent clinical practice guidelines, 2012, pp.52, 930~945
  38. Antonaci F, "A review of current European treatment guidelines for migraine", J Headache Pain, 11, pp.13~19 (2010)
  39. "Migraine prophylaxis" (2023)[URL]

이 간행물의 다른 논문 (19건)

Psilocybin, an Effective Treatment for Major Depressive Disorder in Adults - A Systematic ReviewTessa Watford, Naqash Masoodpp. 2-12Vagus Nerves Stimulation: Clinical Implication and Practical Issue as a Neuropsychiatric TreatmentBori Jung, Seung-Hwan Lee, Chaeyeon Yangpp. 13-22Exploring Clinical Subgroups of Participants with Major Depressive Disorder that may Benefit from Adjunctive Minocycline TreatmentGerard Anmella, Alcy Meehan, Melanie Ashton, Giovanna Fico, Michael Maes, Lesley Berk, Michele De Prisco, Ajeet B. Singh, Diego Hidalgo-Mazzei, Iria Grande, Isabella Pacchiarotti, Andrea Murru, Eduard Vieta, Mohammadreza Mohebbi, MIchael Berk, Olivia M. Dean, Seetal Dodd, Chee H. Ng, Gin S. Malhipp. 33-44Is Every Thyroid Antibody a Bad Sign?: The Complex Relationship of Antithyroid Antibodies and Obsessive-compulsive SymptomsEsra Kabadayi-Sahin, Ali Caykoylu, Mustafa Ugurlu, Selcuk Akan, Gorkem Karakas Ugurlu, Ezgi Cisil Erdogan, Emine Ulku Alkanpp. 45-52The Importance of Low-frequency Alpha (8−10 Hz) Waves and Default Mode Network in Behavioral InhibitionChang-Hwan Im, Sungkean Kim, Yong-Wook Kim, Min Jin Jin, Seung-Hwan Leepp. 53-66
원문 보기